KMYY(600518)2023-10-27 16:00Financial Performance - Total revenue for Q3 2023 reached ¥1,157,119,303.01, an increase of 22.71% compared to the same period last year[4] - Net profit attributable to shareholders was -¥22,150,953.01, with a year-to-date net profit of -¥148,009,117.22[4] - The basic earnings per share for Q3 2023 was -¥0.002, while the year-to-date figure was -¥0.011[5] - Total operating revenue for the first three quarters of 2023 reached ¥3,534,121,140.35, a significant increase from ¥2,721,807,708.62 in the same period of 2022, representing a growth of approximately 30%[20] - The net profit for the third quarter of 2023 was a loss of ¥146,538,808.79, an improvement from a loss of ¥885,047,047.11 in the same quarter of 2022[21] - The company's total revenue for the first three quarters of 2023 reached ¥1,616,862,940.41, a significant increase of 45% compared to ¥1,116,263,289.76 in the same period of 2022[29] - Operating profit for the first three quarters of 2023 was reported at a loss of ¥189,931,844.76, compared to a loss of ¥119,186,152.58 in the previous year[29] - The net profit for the first three quarters of 2023 was a loss of ¥188,422,347.76, worsening from a loss of ¥119,186,152.58 in the same period of 2022[30] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥14,564,850,835.72, a decrease of 3.62% from the end of the previous year[5] - The company's total assets decreased to ¥14,564,850,835.72 in Q3 2023 from ¥15,111,759,138.19 in Q3 2022, reflecting a decline of approximately 3.6%[19] - Total liabilities as of Q3 2023 were ¥7,730,794,358.28, down from ¥8,129,210,276.90 in the previous year, showing a reduction of about 4.9%[19] - The total liabilities decreased to ¥5,230,064,979.59 from ¥5,459,104,498.52 year-over-year[28] - The total equity attributable to shareholders decreased to ¥6,800,751,639.31 in Q3 2023 from ¥6,947,130,703.24 in the previous year, indicating a decrease of approximately 2.1%[19] - The total equity decreased to ¥11,786,171,788.44 from ¥11,971,572,385.21 year-over-year[28] Cash Flow - Cash flow from operating activities was -¥253,310,510.35 year-to-date, indicating ongoing cash flow challenges[4] - The total cash inflow from operating activities for the first three quarters of 2023 was approximately CNY 4.09 billion, compared to CNY 2.89 billion in the same period of 2022, representing an increase of about 41.7%[23] - The net cash flow from operating activities for Q3 2023 was negative CNY 253.31 million, an improvement from negative CNY 336.96 million in Q3 2022[24] - The total operating cash outflow for Q3 2023 was CNY 4.35 billion, compared to CNY 3.23 billion in Q3 2022, indicating an increase of approximately 34.7%[24] - The cash flow from investing activities for Q3 2023 was negative CNY 5.50 million, an improvement from negative CNY 12.77 million in Q3 2022[24] - The cash flow from financing activities for Q3 2023 was negative CNY 81.98 million, compared to negative CNY 55.66 million in Q3 2022[24] Expenses - Research and development expenses increased by 95.81% due to greater investment in formula granule projects[8] - The company reported a significant increase in sales expenses by 47.21% due to revenue growth and corresponding promotional costs[8] - Total operating costs for the third quarter of 2023 were ¥3,835,871,841.64, compared to ¥3,032,710,230.00 in the previous year, indicating an increase of about 26.5%[21] - The company reported a significant increase in tax expenses, which rose to ¥53,978,321.68 in Q3 2023 from ¥13,196,645.19 in Q3 2022, representing a growth of over 300%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 196,101[10] - The largest shareholder, Guangdong Shennong Enterprise Management Partnership, holds 3,509,413,788 shares, accounting for 25.31% of total shares[10] - The company has a significant portion of its shares pledged, with 715,509,782 shares pledged by Kangmei Industrial Investment Holdings[10] Legal and Regulatory Matters - The company has recognized a provision for pending litigation amounting to ¥609,162,800, which reduced the net profit attributable to shareholders for 2022[14] - The company is currently appealing a court ruling regarding a financial loan dispute, with a principal amount of ¥2,819,894,700.00 involved[13] - The company’s subsidiary, Kangmei Traditional Chinese Medicine City (Puning), was involved in bankruptcy proceedings but reached a settlement on October 26, 2023[15] Inventory and Receivables - Accounts receivable decreased to ¥1,840,911,967.54 from ¥1,964,955,319.56 year-over-year[17] - Inventory increased to ¥2,813,773,964.02 from ¥2,750,692,813.49 year-over-year[17] - The inventory as of September 30, 2023, was CNY 688.44 million, slightly up from CNY 682.11 million at the end of 2022[26]